PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “BACTERIAL VACCINES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1990

[Complement activation by killed polyvalent bacterial vaccine on the pleurodesis].

Broncasma Berna (B.B.) prepared from killed polyvalent bacterial vaccine is used as a pleural irritant for pleurodesis on patients with spontaneous pneumothorax. The effects of B.B. on the complement system in vivo after injections into pleural spaces were investigated. Five patients with spontaneous pneumothorax underwent intrapleural injections of B.B. Increased body temperatures with positive C-reactive proteins and increased polymorphonuclear leukocyte counts in peripheral blood were observed in all patients. Serum levels of complement components (Clq, Cls, C4, C3 and B), hemolytic activity of complement (CH50) and plasma levels of C3a were gradually elevated after intrapleural injections of B.B. Analysis of pleural fluids from 4 patients showed that levels of C3a and C5a were increased compared with plasma levels, and an accumulation of polymorphonuclear leukocytes were observed. These findings suggest that intrapleural injections of B.B. activate the complement system and cause inflammatory reactions accompanied by an increase of C3a and C5a and an accumulation of polymorphonuclear leukocytes. Such inflammatory reactions might inversely induce the synthesis of complement components and promote the migration of polymorphonuclear leukocytes from bone marrow. The deposit of fibrin during these inflammatory processes might contribute to the development of pleurodesis. These inflammatory reactions might be mediated through the activation of the classical complement pathway by B.B.

Adult↗
PubMed2001

Bioinformatics: use in bacterial vaccine discovery.

Bioinformatics has now become a common laboratory name for groups studying genomic sequences. It is composed of many different, yet interrelated scientific fields such as genomics, proteomics, and transcriptional profiling. The availability of complete genomic sequences, especially prokaryotic organisms, allows one to rapidly identify, analyze, and clone genes of interest. For bacterial vaccine discovery, one can "mine" the genomic sequence for potential surface targets using various algorithms, characterize these gene targets, and produce primers for cloning, all before one enters the wet laboratory. This review will focus on various genomic mining tools/algorithms available for predicting open reading frames and their associated annotation (if known), physical and functional characterization, and cellular localization. Finally, examples are given of how all of this is being used for the identification of potential bacterial vaccine candidates.

Animals↗
PubMed2000

Aromatic-dependent salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them.

The development of live bacterial vaccines is reviewed, in particular aromatic-dependent Salmonella, either for protection against the corresponding infections (including typhoid fever) or as carrier-presenter of antigens of unrelated pathogens or of DNA specifying them. Aromatic-dependent Salmonella live vaccines are also compared with BCG and Ty21a and the recent records of exceptional situations are discussed in which aroA (deletion) strains of Salmonella typhimurium cause progressive disease in mice.

Animals↗
PubMed1992

Functional and metabolic changes of guinea pig peritoneal macrophages induced by bacterial vaccines.

Phagocytic activity of peritoneal macrophages of guinea pigs injected subcutaneously with bacterial vaccines was found to be increased. The phagocytic index remained unchanged or was decreased. In addition, a decreased candidacidal activity was observed. Metabolic activation of macrophages, measured by the INT test, was inhibited in unstimulated cells while cells stimulated with zymosan or opsonized zymosan exhibited higher values of the INT test as compared with control animals. After injection of vaccines the number of peritoneal macrophages was increased, but the spleen mass decreased.

Animals↗
PubMed1988

Production of tumor necrosis factor in nude mice by muramyl peptides associated with bacterial vaccines.

Gram-negative vaccines can elicit the production of tumor necrosis factor (TNF) in mice primed by muramyl dipeptide (MDP) or by its lipophilic derivative MDP-dipalmitoyl glycerol (MDP-GDP). In mice pretreated with MDP and particularly with MDP-GDP, Bordetella pertussis vaccine was shown to be more effective than typhoid vaccine. The time course of TNF production in the blood did not indicate any difference between the effect of MDP or of MDP-GDP. In both cases the cytotoxic activity reached maximal levels by 2 h after injection of the bacterial preparations and returned to normal values between 3 and 5 h after the challenge. In nude mice, high titers of circulating TNF were also produced by combined treatment with MDP-GDP and bacterial vaccine. Moreover, in tumor-bearing mice the association of MDP or of MDP-GDP to a bacterial vaccine induced a strong hemorrhagic necrosis, whereas each treatment alone was inactive. It was also found that mice were less sick when they were primed with MDP-GDP than with MDP, and when TNF was elicited by B. pertussis instead of lipopolysaccharide. Moreover, nude mice appeared more resistant to shock and to hemoconcentration than normal mice.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1992

Bacterial vaccines: old and new, veterinary and medical.

Developments in veterinary and medical bacterial vaccines are outlined. In the former case, economic considerations are paramount, and cruder, less purified products of proven efficacy continue to be employed. For human use, however, safety and absence of side effects are increasingly demanded. Various examples of human and veterinary vaccines are discussed, and interaction between the two fields is illustrated by reference to the pig-bel disease in New Guinea and the possible aetiology of Sudden Infant Death Syndrome.

Adolescent↗
PubMed1994

Live bacterial vaccines: environmental aspects.

Recombinant DNA technology has greatly accelerated the development of live attenuated bacterial vaccines for cholera, typhoid, and shigellosis. Significant attenuation has been achieved by deleting genes for various virulence determinants, biosynthetic genes, and regulatory genes. As these vaccine candidates move from closed-ward clinical studies to outpatient and field trials, a variety of concerns needs to be addressed about the safety of these vaccines, not only for the vaccinee, but also for the community and the environment. In the case of Vibrio cholerae, specific deletions (delta attRS1 and delta recA) have been introduced into some live vaccine candidates, rendering them incapable of performing homologous and site-specific recombination events that could lead to reacquisition of active cholera toxin genes. Mutations in recA might also limit the persistence of the live vaccine candidate in the environment.

Animals↗
PubMed1995

The history of live bacterial vaccines.

Recent developments have made it possible to construct non-reverting live bacterial vaccine candidates with defined deletions of two or more genes. Such vaccines have proven safe and immunogenic in human volunteers. Since the virulent parent strains are only pathogenic to man (S. typhi, S. flexneri, and V. cholerae), they pose no threat to the environment. Besides holding promise as efficacious vaccines for protection against typhoid fever, bacillary dysentery and cholera, the attenuated strains are well suited as vectors for delivery of heterologous antigenic epitopes from micro-organisms such as Helicobacter pylori, Neisseira gonorrhoeae, rotavirus, HIV and many others. Instead of using a virulent parent bacterium as the starting organism for making a vector, attempts have recently been made to employ non-pathogenic bacteria of the normal human flora, such as Streptococcus gordonii for delivery of foreign antigens. At present, the feasibility of this approach for human beings remains to be proven.

Animals↗
PubMed1990

[Various immunochemical properties of nonspecific bacterial vaccines].

After critical evaluation of the composition and technology of preparation of nonspecific bacterial vaccines (nsb) some of them were withdrawn from the production (Neoflaminum, Neurovaccinum) and replaced with a new one (Polyvaccinum submite). Part of them were modified (media) and modernised (Panodinum, vaccine according to Delbet). Panodine produced at the present is free from bovine bile, which according to the results of the studies is strongly haemolytic for human and animal red blood cells. Thus it was justified to withdraw this component from Neoflaminum and Panodinum preparations. Purity and degree of lysis of these preparations were evaluated on the basis of ratio between nucleic acid absorbance and protein absorbance A260/A280. This allowed to determine if nsb tested are partially lysed and if their production process is reproducible. Our pilot studies on five patients suffering from infectious asthma indicate that a restoration of phagocytic activity of granulocytes and an increase of leukocytes migration after subsequent Panodine injections take place.

Animals↗
PubMed1985

Live attenuated bacterial vaccines: new approaches for safety and efficacy.

Problems arising from reversion to virulence in genetically attenuated bacterial vaccines can be overcome by the combination, in one strain, of multiple temperature-sensitive mutations of identical phenotype. Immunogenicity of attenuated strains may be enhanced by incorporation of mutations which permit limited replication in the vaccinee (thereby increasing antigen mass while minimising the possibility of vaccine reactions) and the expression of genes coding for antigens which are synthesised only during infection of the host.

Animals↗
PubMed1975

[A new vaccinating antigenic fraction obtained from "Vibrio cholerae" II. Biological properties of the Ch1+2 fraction compared with the bacterial vaccine (author's transl)].

This fraction inoculated into mice protects against experimental infection. This fraction induces in various experimental animals serological modifications which are characterized by a rise in the vibriocidal effect of the serum. Controlled experiments in animals and humans showed that the vibriocidal effect is greater than the one obtained by the bacterial vaccine and persist far more longer. The vibriocidal power of the serum can also be obtained at titers relatively high when the fraction is given by the oral route. The in situ vaccination reduces the duration and the numbers of the excreted bacteries in germ free and pathogen free mice.

Animals↗
PubMed2001

Priming of memory but not effector CD8 T cells by a killed bacterial vaccine.

Killed or inactivated vaccines targeting intracellular bacterial and protozoal pathogens are notoriously ineffective at generating protective immunity. For example, vaccination with heat-killed Listeria monocytogenes (HKLM) is not protective, although infection with live L. monocytogenes induces long-lived, CD8 T cell-mediated immunity. We demonstrate that HKLM immunization primes memory CD8 T lymphocyte populations that, although substantial in size, are ineffective at providing protection from subsequent L. monocytogenes infection. In contrast to live infection, which elicits large numbers of effector CD8 T cells, HKLM immunization primes T lymphocytes that do not acquire effector functions. Our studies show that it is possible to dissociate T cell-dependent protective immunity from memory T cell expansion, and that generation of effector T cells may be necessary for long-term protective immunity.

Animals↗